Skip to main content

Advertisement

Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma

Fig. 3

Synergistic inhibition of AKT and NF-κB pathway. a Cell lines were treated with NVP-Bez235 20nM and lenalidomide 2 μM alone or in combination for 72 h. Western blot analysis was performed to identify the expression of total Akt, p-Akt (Ser 473) and p-Akt (Thr308). b Western blot for Ikkα, Ikkβ, p-Ikkα/β, IΚBα, p-IΚBα, NF-κB and p-NF-κB

Back to article page